A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

PHASE4CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

July 31, 2006

Conditions
Glaucoma, Open AngleOcular Hypertension
Interventions
DRUG

Xalacom

DRUG

Cosopt

Trial Locations (25)

13385

Pfizer Investigational Site, Marseille

14033

Pfizer Investigational Site, Caen

16132

Pfizer Investigational Site, Genova

20052

Pfizer Investigational Site, Monza (MI)

20132

Pfizer Investigational Site, Milan

41110

Pfizer Investigational Site, Larissa

44800

Pfizer Investigational Site, Saint-Herblain

56126

Pfizer Investigational Site, Pisa

63003

Pfizer Investigational Site, Clermont-Ferrand

64283

Pfizer Investigational Site, Darmstadt

64297

Pfizer Investigational Site, Darmstadt

66013

Pfizer Investigational Site, Chieti

68100

Pfizer Investigational Site, Alexandroupoli

69437

Pfizer Investigational Site, Lyon

71100

Pfizer Investigational Site, Foggia

71110

Pfizer Investigational Site, Heraklion

73614

Pfizer Investigational Site, Schorndorf

76829

Pfizer Investigational Site, Landau / Pfalz

82319

Pfizer Investigational Site, Starnberg

93128

Pfizer Investigational Site, Regenstauf

546 36

Pfizer Investigational Site, Thessaloniki

703 61

Pfizer Investigational Site, örebro

205 02

Pfizer Investigational Site, Malmo

431 80

Pfizer Investigational Site, Mölndal

851 86

Pfizer Investigational Site, Sundsvall

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00140049 - A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma | Biotech Hunter | Biotech Hunter